Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of serum thymus factor in preparation of protecting drugs of antineoplastic drugs, and tumour physical and chemical treatment drugs

A technology for serum thymus factor and drug, which is applied in the field of application of serum thymus factor in the preparation of antitumor drugs, protective drugs for tumor physics and chemotherapeutic drugs

Inactive Publication Date: 2012-11-14
中国生化制药工业协会
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there are no patents and research reports on the application of FTS as an anti-tumor and immune-enhancing drug at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of serum thymus factor in preparation of protecting drugs of antineoplastic drugs, and tumour physical and chemical treatment drugs
  • Application of serum thymus factor in preparation of protecting drugs of antineoplastic drugs, and tumour physical and chemical treatment drugs
  • Application of serum thymus factor in preparation of protecting drugs of antineoplastic drugs, and tumour physical and chemical treatment drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] This embodiment relates to the results of the EAC ascites tumor group

[0053] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model mice were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the doses were 0.25 mg·kg -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; the positive drug group, 5-fluorouracil, once every other day, three times in total. The results are shown in Table 1:

[0054] Table 1 FTS is used for the result of anti-EAC ascites tumor drug ( n=10)

[0055]

[0056] △△ P△△△ P<0.001 compared with blank group; life extension rate compared with blank group.

[0057] The results in Table 1 show that the survival situat...

Embodiment 2

[0059] This example relates to the results of the H22 solid tumor group

[0060] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model mice were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the doses were 0.25 mg·kg -1 , medium dose 0.125mg·kg -1 , low dose 0.0625mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide administered once. The results are shown in Table 2.

[0061] Table 2 FTS is used for the result of anti-H22 solid tumor drug ( n=10)

[0062]

[0063] △△ P△△△ P<0.001 compared with blank group; tumor inhibition rate compared with blank group.

[0064] The results in Table 2 show that the tumor inhibition rate of the high-dose group and the middle-dose grou...

Embodiment 3

[0066] This embodiment relates to the results of the Walker-256 tumor group

[0067] Administration by subcutaneous injection, animal inoculation on day 0, culture status checked on day 1, if no contamination, animals were weighed and randomly grouped to start administration. The tumor model rats were randomly divided into 5 groups, which were high-dose group, middle-dose group, low-dose group, positive control group and blank group, and the dose was 2.2 mg·kg -1 , medium dose 1.1mg·kg -1 , low dose 0.55mg·kg -1 , except the positive drug group, administered once a day for 14 consecutive days; cyclophosphamide administered once. The results are shown in Table 3.

[0068] The next day after the last administration in the treatment group, the solid tumors were dissected out and weighed, and the tumor inhibition rate was calculated. The tumor inhibition rates of the administration groups were all greater than 30%, and there was a quantitative-effect relationship, and the cura...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a serum thymus factor (FTS) in preparation of protecting drugs of antineoplastic drugs, and tumor physical and chemical treatment drugs. The test results show that the administration groups and normal saline groups of tumor-bearing mice and W256 rats have significant difference and the tumor static rate is more than 30%, so that the antitumor effect of the FTS is definite. The FTS is capable of improving the immunological competence of the organism in many ways and strengthening the organism immune system. The FTS is nontoxic, the produced side effects are lower, and the range of the useful effect dose is wider and the safety range is larger. The research on the FTS as the protecting drug of tumor physical and chemical treatment drugs is found that the FTS obviously protects the organism immune indexes. Therefore, the FTS is capable of providing a new target and development direction for clinically treating the tumors.

Description

[0001] This application is aimed at the parent case of Chinese patent application: 200710002734.3, filing date: January 25, 2007, title of invention: use of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs; divisional application No. 201010218238.3, application date: January 25, 2007, divisional application submission date: July 6, 2010, title of invention: use of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs The second divisional application of the patent application. technical field [0002] The invention relates to a new application of biochemical substances in pharmaceutical engineering, more specifically the application of serum thymus factor in the preparation of anti-tumor drugs, protective drugs for tumor physical and chemical therapy drugs or immune-enhancing drugs. Background technique [0003] Cancer is one of the m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61P35/00
Inventor 徐康森乐嘉静廖晓泉王悦张长平李湛君
Owner 中国生化制药工业协会
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com